ShockWave Medical, Inc. Overview
Pro stress-test →ShockWave Medical develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases. The company was acquired by Johnson & Johnson (JNJ) and delisted in May 2024, representing a major exit for the cardiovascular device innovator.
Strategic Profile
Pro stress-test →IVL uses pulsatile sonic pressure waves to fracture calcified deposits within arteries, minimizing trauma to surrounding soft vascular tissue. The company built a broad portfolio spanning peripheral, coronary, and structural heart applications, positioning it as a leader in addressing severely calcified vascular disease—a high-value surgical challenge for J&J's cardiovascular division.
Competitive Landscape
Pro stress-test →Direct competitors in peripheral and coronary intervention include Philips (atherectomy and angioplasty), Boston Scientific (vascular intervention), and Medtronic (peripheral/coronary devices). Structurally, no direct competitors match IVL's sonic pressure wave approach for calcified lesions, giving J&J a differentiated technology in a high-margin space.
Industry Context
ShockWave Medical, Inc. operates in Interventional cardiology and peripheral vascular devices.
Key facts
Founded: 2009 · Headquarters: Santa Clara, California · Employees: 1,000–5,000 · Revenue: $186.0M (Q3 2023) · Market cap: N/A - Acquired